Indian drugs are cheaper says govt

NEW DELHI

Central govt. defended its decision to end the custom duty exemption for import of 76 LIFE SAVING DRUGS including those for the treating cancer, AIDS, Hemophilia. Government has said Indian manufacturers are already selling most of these drugs at cheaper prices.

Govt. also claimed there will only be marginal increases in prices of these imported drugs due to exemption withdrawl. Health ministry official also said ”In case of 95% of these drugs the custom duty is only 2.5%,so if there is a increase it would be very marginal .While  the medicine directly impact the treatment of crucial health problems like HIV ,AIDS and HAEMOPHILLIA, the official also said majority of such patients are treated by Govt. hospitals. The list of 76 medicines also contains pharmaceuticals ingredients.

A notification issued by CENTRAL BOARD OF EXCISE AND CUSTOMS had withdrawn the customs duty exemption on the impact of 76 drugs. They are used in treatment of diseases like PARKINSONS DISEASE, BONE DISEASES,KIDNEY STONES,BACTERIAL INFECTION, ARTHRITIS,LUPUS .

  • Related Posts

    NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

    The officials identified the substance as Alprazolam manufactured illegally at the lab. HYDERABAD: In one of the largest such seizures in recent times, the Narcotics Control Bureau (NCB), Hyderabad, raided…

    Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

    New Delhi: The Ministry of AYUSH has detailed its regulatory framework and ongoing initiatives to monitor heavy metal content in traditional medicines, responding to parliamentary concerns over quality and safety…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices